Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

211 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ACCELERATE Paediatric Strategy Forums: an advance for oncological drug development?
Pearson ADJ, de Rojas T, Karres D, Reaman G, Scobie N, Fox E, Lesa G, Ligas F, Norga K, Nysom K, Pappo A, Weigel B, Weiner S, Vassal G. Pearson ADJ, et al. Among authors: weigel b. Lancet Oncol. 2022 Nov;23(11):1354-1357. doi: 10.1016/S1470-2045(22)00619-2. Lancet Oncol. 2022. PMID: 36328007 No abstract available.
Larotrectinib for Newly Diagnosed Infantile Fibrosarcoma and Other Pediatric NTRK Fusion-Positive Solid Tumors (Children's Oncology Group ADVL1823).
Laetsch TW, Voss S, Ludwig K, Hall D, Barkauskas DA, DuBois SG, Ronan J, Rudzinski ER, Memken A, Robinson K, Sorger J, Reid JM, Bhatla T, Crompton BD, Church AJ, Fox E, Weigel BJ. Laetsch TW, et al. Among authors: weigel bj. J Clin Oncol. 2024 Dec 9:JCO2401854. doi: 10.1200/JCO-24-01854. Online ahead of print. J Clin Oncol. 2024. PMID: 39652801
A Phase 1 Study of ABI-009 (Nab-sirolimus) in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors-A Children's Oncology Group Pediatric Early Phase Clinical Trial Network Study ADVL1514.
Cramer SL, Reddy AT, Minard CG, Voss S, Fox E, Liu X, Denic K, Reid JM, Weigel BJ. Cramer SL, et al. Among authors: weigel bj. Cancer Med. 2024 Nov;13(21):e70376. doi: 10.1002/cam4.70376. Cancer Med. 2024. PMID: 39487711 Free PMC article. Clinical Trial.
Toxicity Profile of eBAT, a Bispecific Ligand-Targeted Toxin Directed to EGFR and uPAR, in Mice and a Clinical Dog Model.
Dicovitsky RH, Schappa JT, Schulte AJ, Lang HP, Kuerbitz E, Roberts S, DePauw TA, Lewellen M, Winter AL, Stuebner K, Buettner M, Reid K, Bergsrud K, Pracht S, Chehadeh A, Feiock C, O'Sullivan MG, Carlson T, Armstrong AR, Meritet D, Henson MS, Weigel BJ, Modiano JF, Borgatti A, Vallera DA. Dicovitsky RH, et al. Among authors: weigel bj. Toxins (Basel). 2024 Aug 26;16(9):376. doi: 10.3390/toxins16090376. Toxins (Basel). 2024. PMID: 39330834 Free PMC article.
Palbociclib in Solid Tumor Patients With Genomic Alterations in the cyclinD-cdk4/6-INK4a-Rb Pathway: Results From National Cancer Institute-Children's Oncology Group Pediatric Molecular Analysis for Therapy Choice Trial Arm I (APEC1621I).
Macy ME, Mody R, Reid JM, Piao J, Saguilig L, Alonzo TA, Berg SL, Fox E, Weigel BJ, Hawkins DS, Mooney MM, Williams PM, Patton DR, Coffey BD, Roy-Chowdhuri S, Takebe N, Tricoli JV, Janeway KA, Seibel NL, Parsons DW. Macy ME, et al. Among authors: weigel bj. JCO Precis Oncol. 2024 Sep;8:e2400418. doi: 10.1200/PO-24-00418. JCO Precis Oncol. 2024. PMID: 39298716 Clinical Trial.
211 results